📊 TNGX Key Takeaways
Is Tango Therapeutics, Inc. (TNGX) a Good Investment?
Pre-revenue pharmaceutical company with improving loss trajectory and fortress balance sheet ($157.8M cash, zero debt), but significant quarterly cash burn ($44.4M) and lack of commercial validation create substantial execution risk. Strong balance sheet provides multi-year runway, but company must achieve product commercialization to justify continued investment.
Tango Therapeutics, Inc. Key Strengths (TNGX)
- Fortress balance sheet with $157.8M in cash and zero long-term debt, providing approximately 3.6 years of runway at current burn rate
- Improving loss trajectory with 22.0% YoY improvement in net income and 26.9% improvement in diluted EPS, indicating operational progress
- Exceptional liquidity position with 27.38x current ratio and minimal liabilities ($44.3M vs. $435.8M assets)
TNGX Stock Risks: Tango Therapeutics, Inc. Investment Risks
- Zero revenue indicates pre-commercial stage with binary execution risk dependent on pipeline success and regulatory approval
- Operating cash burn of $44.4M quarterly is unsustainable long-term without revenue generation or further capital raises
- Pharmaceutical development and regulatory risk including clinical trial failures, FDA rejection, and competitive pressures
- Significant dilution risk if additional capital raises become necessary before achieving revenue milestones
Key Metrics to Watch
- Quarterly revenue recognition and pathway to profitability
- Cash burn rate and remaining cash runway sustainability
- Clinical trial progress, regulatory milestones, and product pipeline advancement
Tango Therapeutics, Inc. (TNGX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 27.38x current ratio provides a solid financial cushion.
TNGX Profit Margin, ROE & Profitability Analysis
TNGX vs Healthcare Sector: How Tango Therapeutics, Inc. Compares
How Tango Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tango Therapeutics, Inc. Stock Overvalued? TNGX Valuation Analysis 2026
Based on fundamental analysis, Tango Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tango Therapeutics, Inc. Balance Sheet: TNGX Debt, Cash & Liquidity
TNGX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tango Therapeutics, Inc.'s revenue has grown significantly by 68% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.08 indicates the company is currently unprofitable.
TNGX Revenue Growth, EPS Growth & YoY Performance
TNGX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$39.9M | $-0.32 |
| Q3 2025 | $11.6M | $15.9M | $0.13 |
| Q2 2025 | $3.2M | -$25.6M | $-0.24 |
| Q1 2025 | $5.4M | -$37.9M | $-0.35 |
| Q3 2024 | $10.7M | -$20.7M | $-0.23 |
| Q2 2024 | $14.6M | -$20.7M | $-0.23 |
| Q1 2024 | $5.8M | -$28.0M | $-0.32 |
| Q3 2023 | $6.9M | -$20.7M | $-0.23 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Tango Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TNGX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tango Therapeutics, Inc. (CIK: 0001819133)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TNGX
What is the AI rating for TNGX?
Tango Therapeutics, Inc. (TNGX) has an AI grade of B with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TNGX's key strengths?
Claude: Fortress balance sheet with $157.8M in cash and zero long-term debt, providing approximately 3.6 years of runway at current burn rate. Improving loss trajectory with 22.0% YoY improvement in net income and 26.9% improvement in diluted EPS, indicating operational progress.
What are the risks of investing in TNGX?
Claude: Zero revenue indicates pre-commercial stage with binary execution risk dependent on pipeline success and regulatory approval. Operating cash burn of $44.4M quarterly is unsustainable long-term without revenue generation or further capital raises.
What is TNGX's revenue and growth?
Tango Therapeutics, Inc. reported revenue of $0.0.
Does TNGX pay dividends?
Tango Therapeutics, Inc. does not currently pay dividends.
Where can I find TNGX SEC filings?
Official SEC filings for Tango Therapeutics, Inc. (CIK: 0001819133) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TNGX's EPS?
Tango Therapeutics, Inc. has a diluted EPS of $-0.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TNGX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Tango Therapeutics, Inc. has a B grade with 68% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TNGX stock overvalued or undervalued?
Valuation metrics for TNGX: ROE of -11.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TNGX's AI grade for 2026?
Our dual AI analysis gives Tango Therapeutics, Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TNGX's free cash flow?
Tango Therapeutics, Inc.'s operating cash flow is $-44.4M, with capital expenditures of $2.0K.
How does TNGX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -11.6% (avg: 15%), current ratio 27.38 (avg: 2).